ABBV (NYSE) - AbbVie | Stock Price & Analysis

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00287Y1091
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for ABBV (NYSE) - AbbVie | Stock Price & Analysis


Market Cap in USD 251,395m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2013-01-02


Fundamental 5.38
Dividend 9.01
Performance 5y 5.98
Rel. Performance vs Sector 1.84
Analysts 3.83
Fair Price Total Ret. 144.53
Fair Price DCF todo


Growth TTM -8.34%
CAGR 5y 13.91%
CAGR / Mean Drawdown 1.54
Sharpe Ratio TTM -0.69
Alpha vs SP500 TTM -19.21
Beta vs SP500 5y weekly 0.66
CAPM 7.05%
Average Daily Range 2m 1.73%
Reversal Oscillator 63.86
Volatility GJR Garch 1y 23.42%
Price / SMA 50 -1.15%
Price / SMA 200 -1.68%
Current Volume 9297.4k
Average Volume 20d 5359.1k


Yield TTM 4.16%
Yield on Cost 5y 7.98%
Dividends CAGR 5y 9.46%
Consistency of Dividends all time 100.0%